NDAINTRAVENOUSSOLUTION
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE (norepinephrine bitartrate) by Baxter is (alpha-adrenergic action) and an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action). First approved in 2022.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Norepinephrine bitartrate in 0.9% sodium chloride is a catecholamine vasopressor agent administered intravenously for acute hypotension management, primarily in critical care settings. It functions through dual alpha-adrenergic and beta-adrenergic mechanisms to restore blood pressure and tissue perfusion in hemodynamically unstable patients.
Peak12.8 years to LOE
Product is at peak commercial maturity with established hospital formulary presence; brand team likely focuses on loyalty and clinical evidence building rather than rapid expansion.
Mechanism of Action
(alpha-adrenergic action) and an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action).
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on norepinephrine bitartrate offers stable, mission-critical healthcare impact in acute care environments with established market presence and predictable career trajectory. Roles emphasize clinical credibility, hospital relationships, and regulatory maintenance rather than market expansion or launch complexity.
Hospital/IDN Account ManagerClinical Educator
Worked on NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE at Baxter? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.